MOBQ · Mobiquity Technologies, Inc.

Not applicable.

Includes (i) 59,211 shares underlying warrants exercisable at $60 per share, (ii) 2,333 shares underlying options exercisable at $68.48 per share, (iii) 100,000 shares underlying options exercisable at $.20 per share, (iv)100,000 shares underlying a convertible note at $1.00 per share, (v) options to purchase 250,000 shares exercisable at $2.45 per share, and (vi) options to purchase 250,000 exercisable at $1.10 per share.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

Not applicable.

Includes (i) 59,211 shares underlying warrants exercisable at $60 per share, (ii) 2,333 shares underlying options exercisable at $68.48 per share, (iii) 100,000 shares underlying options exercisable at $.20 per share, (iv)100,000 shares underlying a convertible note at $1.00 per share and (v) options to purchase 250,000 shares exercisable at $2.45 per share.

Represents interest paid on a convertible note

The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

Not applicable.

Includes (i) 59,211 shares underlying warrants exercisable at $60 per share, (ii) 2,333 shares underlying options exercisable at $68.48 per share, (iii) 100,000 shares underlying options exercisable at $.20 per share and (v) options to purchase 250,000 shares exercisable at $2.45 per share.

Not applicable.

Not applicable

Not applicable.

Not applicable

The securities listed in Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

Not applicable.

Includes (i) 420,000 common shares underlying convertible notes, (ii) 59,211 shares underlying warrants exercisable at $60 per share, (iii) 2,333 shares underlying options exercisable at $68.48 per share, (iv) 100,000 shares underlying options exercisable at $.20 per share and (v) options to purchase 250,000 shares exercisable at $2.45 per share.

Not applicable

Not applicable

Not applicable.

The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust.

Not applicable.

Includes (i) 420,000 common shares underlying convertible notes, (ii) 59,211 shares underlying warrants exercisable at $60 per share, (iii) 2,333 shares underlying options exercisable at $68.48 per share and (iv) 100,000 shares underlying options exercisable at $.20 per share.

Includes dividend shares issued upon conversion.

The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust.

The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust.

Not applicable.

The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust.

Not applicable.

Not applicable

Not applicable

Not applicable.

Not applicable

Not applicable.

The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495.

Not applicable

Not applicable.

The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495.

Not applicable.

The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495.

Not applicable.

Salkind and his trust invested an additional $1,200,000 plus converted the $300,000 principal loan plus interest of $3,495 (totaling$1,503,495) into shares of Series G Preferred Stock, convertible at holders option at any time into common stock at an effective price of $.50 per share.

The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. Salkind has the right to convert $300,000 loan into common stock at $.70 per share or into the terms of a financing completed before November 30, 2023.

Salkind and his trust invested an additional $1,200,000 plus converted the $300,000 principal loan plus interest of $3,495 (totaling$1,503,495) into shares of Series G Preferred Stock, convertible at holders option at any time into common stock at an effective price of $.50 per share.

Not applicable.

The 448,535 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee.

Not applicable.

The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. Salkind has the right to convert $300,000 loan into common stock at $.70 per share or into the terms of a financing completed before November 30, 2023.

The 4,478,017 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee.

The 3,092,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee.

Not applicable.

Not applicable

Not applicable.

The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

The board of directors of the issuer accepted Dr. Salkind's offer to convert $510,000 of convertible notes at a reduced conversion price of $1.25 per share into 408,000 common shares and warrants to purchase 204,000 shares at an exercise price of $4.00 per share through September 30, 2029.

Not applicable.

Left blank intentionally.

The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

The board of directors of the issuer accepted Dr. Salkind's offer to convert $510,000 of convertible notes at a reduced conversion price of $1.25 per share into 408,000 common shares and warrants to purchase 204,000 shares at an exercise price of $4.00 per share through September 30, 2029.

Not applicable.

1,441,500 derivative securities include the following: (i) 390,625 common stock purchase warrants exercisable at $4.00 per share through September 2023; (ii) 10-year options to purchase 35,000 shares granted on December 8, 2021; and (iii) warrants to purchase 1,015,875 shares exercisable through September 30, 2029 which were issuable on June 30, 2022 as a result of the note conversion.

The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

Not applicable

The 2,484,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

After the close of business on March 29, 2022 and prior to the close of the market on March 30, 2022, the board of directors of the issuer accepted Dr. Salkind's offer to convert $2,052,500 of convertible notes at a reduced conversion price of $1.50 per share into 1,368,333 common shares and warrants to purchase 684,166 shares at an exercise price of $4.00 per share through September 30, 2029. A portion (i.e. $1,542,500) of the note conversion came directly from Dr. Salkind and his wife and a portion (i.e.$510,000) of the note conversion came directly from the trust that Dr. Salkind is the trustee.

Not applicable.

1,237,500 derivative securities include the following: (i) 127,500 shares underlying $510,000 of debt, convertible at $4.00 per share (excluding 50% warrant coverage - i.e. 63,750 warrants, exercisable at $4.00 per share through September 30, 2029, if and when issued); (ii) 390,625 common stock purchase warrants exercisable at $4.00 per share through September 2023; (iii) 10-year options to purchase 35,000 shares granted on December 8, 2021; and (iv) warrants to purchase 686,166 shares exercisable through September 30, 2029 which were issuable on March 30, 2022 as a result of the note conversion.